IDEAYA Biosciences, Inc. (IDYA) Q2 2021 Earnings Results

IDEAYA Biosciences Misses on EPS, Stock Down 1.59%

The earnings report indicates that IDEAYA Biosciences is still in a development phase, with significant losses reported. The stock reaction of a 1.59% decline reflects investor concerns over the lack of revenue and guidance. Without clear financial targets, investors may remain cautious about the company's near-term prospects.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.33	N/A	-392.54%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a cautious outlook, emphasizing the importance of their research pipeline. There was no guidance provided for future performance.

Management did not provide specific insights on revenue expectations.

The focus remains on ongoing clinical trials and research initiatives.

IDEAYA Biosciences Misses on EPS, Stock Down 1.59%

Key numbers

Management commentary

IDEAYA Biosciences, Inc.

More earnings this week

IDEAYA Biosciences Misses on EPS, Stock Down 1.59%

Key numbers

Management commentary